Clinical Trials Directory

Trials / Unknown

UnknownNCT00994305

Protective Effect of N-acetylcysteine on Early Outcomes of Deceased Renal Transplant

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
74 (estimated)
Sponsor
University of Sao Paulo General Hospital · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Investigate the therapeutic effects of the antioxidant N-acetylcysteine on early outcomes of deceased renal transplant patients.

Detailed description

Investigate the therapeutic effects of 600 mg bid po of N-acetylcysteine on early outcomes of deceased renal transplant patients regarding oxidative stress and renal function. Adult primary graft recipients of deceased renal donors will be randomly assign to treatment (NAC) or control group and prospectively evaluated for 90 days. Treatment group will receive N-acetylcysteine 600 mg bid po from 0 to 7th postoperative day (PO). Renal function will be determined by serum creatinine, Cockroft-Gault estimated GFR (eGFR) at 7th, 15th, 30th, 60th and 90th PO and dialysis free Kaplan-Meier estimate curve. Serum levels of thiobarbituric acid reactive substances (TBARS), which are markers of lipid peroxidation and oxidative stress, will be determined using the thiobarbituric acid assay from 0-7th PO. Statistical analysis will be performed using SPSS 16.0.

Conditions

Interventions

TypeNameDescription
DRUGN-acetylcysteine600 mg bid po 0-7 PO
DRUGcontrolNo treatment: standard care provided. No N-acetylcysteine administration.

Timeline

Start date
2005-04-01
Primary completion
2008-06-01
Completion
2009-12-01
First posted
2009-10-14
Last updated
2009-10-14

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT00994305. Inclusion in this directory is not an endorsement.